Achillion Reports First Quarter 2018 Financial Results and Management Transition
02. Mai 2018 06:35 ET
|
Achillion Pharmaceuticals, Inc.
- Plans for clinical data in C3 glomerulopathy (C3G) and for paroxysmal nocturnal hemoglobinuria (PNH) remain on track for 2018 - - Joseph Truitt appointed Chief Executive Officer - NEW HAVEN,...
Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy
26. Februar 2018 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a biopharmaceutical company focused on advancing small molecule factor D inhibitors to modulate the...
Achillion Announces Restructuring to Advance Corporate Strategy; Announces 2017 Fourth Quarter and Full Year Financial Results
22. Februar 2018 06:05 ET
|
Achillion Pharmaceuticals, Inc.
Corporate restructuring expected to enable Achillion to focus on goal of advancing its clinical and late-stage preclinical portfolio while maintaining a strong balance sheet Joseph Truitt, Chief...
Achillion to Present at the Leerink Partners 7th Annual Global Healthcare Conference
09. Februar 2018 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
CORRECTION - Achillion Pharmaceuticals, Inc.
20. Dezember 2017 12:12 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) -- In the news release issued earlier today by Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), please be advised the headline should read "Achillion...
Achillion Initiates Phase I First-In Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D
20. Dezember 2017 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a pharmaceutical company focused on advancing small molecule inhibitors of factor D in the...
Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs
01. November 2017 16:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended September 30, 2017. For the third...
USPTO Grants Composition of Matter Patent to Achillion for ACH-4471, First-in-Class Small Molecule Complement Alternative Pathway Factor D Inhibitor
24. Oktober 2017 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued a U.S. Patent to...
Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference
02. Mai 2017 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., May 02, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pathway Factor D Inhibitors
21. März 2017 16:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., March 21, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued the first U.S. Patent...